Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with FLOT and Trastuzumab in HER2+ Esophagogastric Junction Adenocarcinoma
NCT06681298Phase 2Active, not recruiting
- Start
- May 2024
- Primary completion
- May 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in adenocarcinoma of the esophagogastric junction (AEG). Started May 2024; status: active, not recruiting.
02
Drugs
03
Conditions
adenocarcinoma of the esophagogastric junction (AEG)
Beyond the preview
Go deeper on NCT06681298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06681298.